The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 353:2618-2619 December 15, 2005 Number 24
NextNext

Alendronate and Parathyroid Hormone

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Black, D. M.
-Related Article
by Cosman, F.
-PubMed Citation
To the Editor: Black et al.1 and Cosman et al.2 (Aug. 11 issue) report that combinations of parathyroid hormone and alendronate are beneficial in the treatment of osteoporosis. However, it appears possible that coexisting subclinical osteomalacia may have clouded both the diagnosis and the interpretation of the results.

In a study of elderly subjects in Ireland with vitamin D deficiency, my colleagues and I observed a surprisingly larger number who had low serum levels of 25-hydroxyvitamin D as well as mildly abnormal calcium, phosphorus, and alkaline phosphatase levels.3,4 Cosman and colleagues found a similar pattern of low serum levels of . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.